Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%
Cstone Pharmaceuticals (HKG:2616) reported a loss for the year attributable to owners of about 367.2 million yuan, down from a loss of 902.7 yuan in the previous year, according to the annual results
基石藥業-B:2023年年報
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor
China's medical products administrator accepted CStone Pharmaceuticals' (HKG:2616) manufacturing localization application for its pralsetinib RET inhibitor, according to a Tuesday filing with the Hong
Cornerstone Pharmaceutical-B (02616.HK): The application for marketing registration of the RET inhibitor Pujihua (platinib capsules) transferred from overseas to domestically produced drugs has been accepted by the Drug Evaluation Center of the State Drug
Gelonghui, April 9 | Cornerstone Pharmaceutical-B (02616.HK) announced that the application for the transfer of the RET inhibitor Pujihua (Platinib capsules) to domestically produced drugs has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center. Previously, Cornerstone Pharmaceuticals' application for marketing registration to transfer another precision medicine, Taijihua (avatinib tablets), to be produced domestically was accepted by the Drug Review Center in June 2023. It is currently under review, and domestic supply is expected to be achieved in 2024. Dr. Yang Jianxin, CEO and Executive Director of Cornerstone Pharmaceuticals, said, “Phuket China
Cornerstone Pharmaceutical-B (02616) granted a total of 11.1979 million restricted share units and 11.20.29 million share options
Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616) issued an announcement. On March 28, 2024, the board of directors of the company decided to grant a total of 11.1979 million restricted share units to 104 restricted share unit grantees in accordance with the restricted share award scheme after the initial public offering. On March 28, 2024, the board of directors of the company decided to grant a total of 11.202,900 share options to 107 share option grantees in accordance with the post-initial public offering employee share ownership plan.
Cornerstone Pharmaceutical-B (02616.HK) announced annual results, losses were drastically reduced by 59.3% and will continue to promote innovative pipeline drugs
On March 27, GLONGHUI | Cornerstone Pharmaceutical-B (02616.HK) announced that for the year ended December 31, 2023, the company's revenue was RMB 463.8 million. The loss during the year decreased from RMB 902.7 million in the previous year to RMB 535.5 million or 59.3% to RMB 367.2 million in the year, mainly due to a sharp reduction in employee costs and the net profit from the transfer of the avonib business. The company continues to develop and deepen relationships with major global strategic partners (including partners in China) and expand commercialization of marketed and advanced drugs,
CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Hong Kong Stock Announcement Nuggets | Fuyao Glass's 2023 profit to mother increased by 18.37% year-on-year to about $5.629 billion, and plans to pay a dividend of $1.3 per share
Important matters: Yadi Holdings (01585) subsidiary plans to acquire all shares of Wuxi Lingbo Electronic Technology for 352 million yuan Kingsley Biotechnology (01548): CARVYKTI was recommended by the US FDA Oncology Drug Advisory Committee for early treatment of patients with recurrent or refractory multiple myeloma Pharmaceutical-B (02616) announced that the fifth indication of sugarimab has been approved in China for first-line treatment of gastric cancer Operating performance: Sinopec Refining and Chemical Engineering (02386) announced that shareholders should account for a profit of 2,335 million yuan YoY 2.2% increase in proposed distribution terminals
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
To the annoyance of some shareholders, CStone Pharmaceuticals (HKG:2616) shares are down a considerable 34% in the last month, which continues a horrid run for the company. For any long-term shareh
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved
Cstone Pharmaceuticals (HKG:2616) said China's National Medical Products Administration (NMPA) approved a supplemental biologics license application (sBLA) for sugemalimab in combination with fluoropy
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 8%, and a new first-line treatment for gastric cancer was approved in China
Cornerstone Pharmaceutical-B (02616) rose more than 8%. As of press release, it rose 8.25% to HK$1.05, with a turnover of HK$2,715,700.
Cornerstone Pharmaceutical-B (02616) announced that the fifth indication for sugarimab has been approved in China for first-line treatment of gastric cancer
Cornerstone Pharmaceutical-B (02616) announced that sugarimab (zegemide) in combination contains...
Cornerstone Pharmaceutical-B (02616.HK) held a board meeting on March 27 to consider and approve the annual results
Gelonghui March 14 | Cornerstone Pharmaceutical-B (02616.HK) announced that the board meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
CSTONE PHARMA-B: DATE OF BOARD MEETING
Insider Purchases Worth CN¥6.54m See Losses As CStone Pharmaceuticals Market Value Drops To HK$1.4b
The recent price decline of 31% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥6.54m worth of shares at an average price of CN¥2.52 in the past 12 months. In
Cornerstone Pharmaceutical (02616) issued an announcement that the company's business is basically carried out according to the plan
Cornerstone Pharmaceuticals (02616) issued a voluntary announcement stating that Cornerstone Pharmaceuticals continues to operate normally, and there have been no major changes in business operations or financial conditions, and the company's business is basically proceeding according to plan.
CStone Pharmaceuticals Removed From Hong Kong Stock Connect; Shares Plunge 26%
CStone Pharmaceuticals (HKG:2616) has been removed from the Hong Kong Stock Connect effective March 4, a Monday filing said. The removal from the Stock Connect program comes after the company was deli
Cornerstone Pharmaceuticals (02616) dropped 25% and was removed from the Hong Kong Stock Connect Securities List
Jinwu Financial News | Cornerstone Pharmaceuticals (02616) fluctuated and declined. As of press release, it fell 25% to HK$1.11, with a turnover of HK$12.117,300. The company announced that as of public information released on February 16, 2024, the company is no longer one of the eligible securities for the Hang Seng Composite Index, and the company will no longer be included in the Hong Kong Stock Connect as of March 4, 2024.
Cornerstone Pharmaceutical-B (02616) fell 3.30% and is now reported at 1.510 yuan, hitting a 52-week low
As of 16:08, Cornerstone Pharmaceutical-B (02616) is down 3.30% from yesterday's closing price and now reports a 52-week low of $1.510; the trading volume is 305.1 million shares, with a turnover of HK$462.1 million.
Why Investors Shouldn't Be Surprised By CStone Pharmaceuticals' (HKG:2616) 25% Share Price Plunge
The CStone Pharmaceuticals (HKG:2616) share price has softened a substantial 25% over the previous 30 days, handing back much of the gains the stock has made lately. The recent drop completes a dis
No Data